Monday, June 14, 2021

Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy

Novavax, Inc. today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial.

Photo by CDC on Unsplash
The study enrolled 29,960 participants across 119 sites in the U.S. and Mexico to evaluate efficacy, safety and immunogenicity, with an emphasis on recruiting a representative population of communities and demographic groups most impacted by the disease.

Posted by at
Labels: , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)